Tetramethylpyrazine is Senolytic in Bone Marrow: Reduces Inflammation and Improves Stem Cell Function in Mice

Today’s open access paper reports on a new senolytic drug candidate, with good-looking data on its effects on the bone marrow environment in aged mice – reducing inflammation, and improving the hematopoietic stem cell pool, among other benefits. Senolytic drugs are those that selectively destroy senescent cells. Cells become senescent constantly, but near all either self-destruct or are destroyed by the immune system. Unfortunately, a tiny fraction linger, and their behavior produces chronic inflammation and degrades tissue function in a variety of ways. Their growing presence is one of the root causes of aging, directly implicated in the progression of many age-related diseases. If, however, senescent cells could be periodically culled, safely and efficiently, this contribution to degenerative aging could be removed entirely.

senolytic drug candidateinflammationhematopoietic stem cellsenescent cellsimmune systemone of the root causes of aging

In recent years, researchers have found a dozen or so senolytic compounds. These are largely well-known to the research community, and most have been tested in dozens of studies, usually for anti-cancer effects. Yet next to no-one was looking for effects on cellular senescence much before six or seven years ago, more is the pity. The best of these senolytics have since been demonstrated to clear


Article originally posted at

Click here for the full story

Privacy Policy / Terms Of Use

Powered by MMD